In addition, subsequent to gut microbial perturbations, altered microbial metabolites in patients with CeD also contribute to the liver damage and steatosis via bile acid signalling pathways (mediated by e.g., the farnesoid X receptor).9 This evidence concerns the gene NR1H4 and cranioectodermal dysplasia.